NTRC Technology Platforms for Precision Oncology
Cell-Based Assays to Determine Genetic Drivers and Biological Pathways for Precision Oncology
Oncolines™ Cancer Cell Lines, Proliferation Assays and Bioinformatics Analysis
- Proliferation assays on a large panel of cancer cell lines aid in patient stratification biomarker discovery
- Bioinformatics analysis on IC50 data and pharmacogenomics for biomarker discovery, drug sensitivity and targeting
SynergyFinder™ Screen for Synergistic Drug and Therapy Combinations
- Determination of synergy for combination therapy by curve-shift analysis and CI values
- Reference dataset of >180 compounds available
- Hypothesis driven experiments as well as broad screening
Mechanistic Cell Biology, In Vitro Assays to Determine Mechanism of Action
- Flexible assay development and screening,
- Proof of concept studies, determination of mechanism of action
- Testing of a wide range of cancer cells, immune cells and primary patient material in vitro
- Primary data and final reports shared via a secured link
- Turnaround time starts at day of arrival of compounds at NTRC and ends with transfer of final report and primary data
NTRC Precision Medicine Services boosts the science of your project, helping you to find mechanistic hypotheses for progressing to the clinic in a well-informed manner
Available on a fee-for-service basis and collaborations via an integrated precision medicine approach.
It is our mission to help you find the informed route to the clinic.
